BOTHELL, Wash.—-Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that it has filed an investigational new drug application to conduct a Phase 1 clinical trial for its lead compound ACU-02 with the U.S.